The clinical application of fruquintinib on colorectal cancer

References

• Cassidy S, Syed BA. Colorectal cancer drugs market. Nat Rev Drug Discov. 2017;16(8):525–526.
   PubMed Web of Science ®Google Scholar
• Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–197.
   PubMedGoogle Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015;27(1):1.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Ansa BE, Coughlin S, Alema-Mensah E, et al. Evaluation of colorectal cancer incidence trends in the United States (2000-2014). J Clin Med. 2018;7(2):22.
   Web of Science ®Google Scholar
• Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev. 2008;17(8):1852–1857.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Suyama K, Baba H. Recent advances in targeting the EGFR signaling pathway for the treatment of metastatic colorectal cancer. Int J Mol Sci. 2017;18(4):752.
   Web of Science ®Google Scholar
• Lee SY, Oh SC. Advances of targeted therapy in treatment of unresectable metastatic colorectal cancer. Biomed Res Int. 2016;2016:7590245.
   PubMed Web of Science ®Google Scholar
• Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther. 2009;16(5):412–420.
   PubMed Web of Science ®Google Scholar
• Winder T, Lenz HJ. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 2010;138(6):2163–2176.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Toiyama Y, Tanaka K, et al. Oncology market research provides a feasible index for standardization of colorectal cancer chemotherapy. Jpn J Clin Oncol. 2011;41(10):1203–1208.
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Inoue T, Taylor RD, et al. Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate. Nat Commun. 2015;6:6706.
   PubMed Web of Science ®Google Scholar
• Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012;109(14):5299–5304.
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551.
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov. 2011;10(4):261–275.
   PubMed Web of Science ®Google Scholar
• Porru M, Pompili L, Caruso C, et al. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57.
   PubMedGoogle Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660–673.
   PubMed Web of Science ®Google Scholar
• Witte D, Thomas A, Ali N, et al. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res. 2002;22(3):1463–1466.
   PubMed Web of Science ®Google Scholar
• Su JL, Yang P-C, Shih J-Y, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell. 2006;9(3):209–223.
   PubMed Web of Science ®Google Scholar
• Su JL, Yen C-J, Chen P-S, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007;96(4):541–545.
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–1645.
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–887.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang J, Li K, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95–115.
   PubMed Web of Science ®Google Scholar
• Bohnert T, Gan L-S. Plasma protein binding: from discovery to development. J Pharm Sci. 2013;102(9):2953–2994.
   PubMed Web of Science ®Google Scholar
• Buscher B, Laakso S, Mascher H, et al. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European bioanalysis forum. Bioanalysis. 2014;6(5):673–682.
   PubMed Web of Science ®Google Scholar
• Howard ML, Hill JJ, Galluppi GR, et al. Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen. 2010;13(2):170–187.
   PubMed Web of Science ®Google Scholar
• Cao JN, Zhang J, Peng W, et al. A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–269.
   PubMed Web of Science ®Google Scholar
• Aderhold C, Faber A, Umbreit C, et al. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. Anticancer Res. 2015;35(4):1951–1959.
   PubMed Web of Science ®Google Scholar
• Zhou S, Shao F, Xu Z, et al. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [(14)C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2017;80(3):563–573.
   PubMed Web of Science ®Google Scholar
• Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22.
   PubMed Web of Science ®Google Scholar
• Li J, Barrios CH, Kim TM, et al. A phase Ib study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer. J Clin Oncol. 2014;32(15):2765–2772.
   Web of Science ®Google Scholar
• Li J, Qin S, Xu R-H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. Jama. 2018;319(24):2486–2496.
   PubMed Web of Science ®Google Scholar
• Burki TK. Fruquintinib for previously treated metastatic colorectal cancer. Lancet Oncol. 2018;19(8):e388.
   PubMed Web of Science ®Google Scholar
• Tampellini M, Sonetto C, Scagliotti GV. Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs. 2016;25(5):507–520.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Bai Y, et al. A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO). J Clin Oncol. 2017;35 (15_suppl):3508–3508. DOI:10.1200/JCO.2017.35.15_suppl.3508
   Google Scholar
• Evaluation(Cde) CFD. Elunate® fruquintinib capsules. 2018.
   Google Scholar
• Shirley M. Fruquintinib: first global approval. Drugs. 2018;78(16):1757–1761.
   PubMed Web of Science ®Google Scholar
• Dekker E, Rex DK. Advances in CRC prevention: screening and surveillance. Gastroenterology. 2018;154(7):1970–1984.
   PubMed Web of Science ®Google Scholar
• Sovich JL, Sartor Z, Misra S. Developments in screening tests and strategies for colorectal cancer. Biomed Res Int. 2015;2015:326728.
   PubMedGoogle Scholar
• Tong F, Ying Y, Pan H, et al. MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC). Bosn J Basic Med Sci. 2018;18(3):252–259.
   PubMed Web of Science ®Google Scholar
• Ying HQ, Peng H-X, He B-S, et al. MiR-608, pre-miR-124-1 and pre-miR26a-1 polymorphisms modify susceptibility and recurrence-free survival in surgically resected CRC individuals. Oncotarget. 2016;7(46):75865–75873.
   PubMedGoogle Scholar
• De Robertis M, Mazza T, Fusilli C, et al. EphB2 stem-related and EphA2 progression-related miRNA-based networks in progressive stages of CRC evolution: clinical significance and potential miRNA drivers. Mol Cancer. 2018;17(1):169.
   PubMedGoogle Scholar
• Barbagallo C, Brex D, Caponnetto A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. Mol Ther Nucleic Acids. 2018;12:229–241.
   PubMedGoogle Scholar
• Wang XY, Li S-N, Zhu H-F, et al. RGC32 induces epithelial-mesenchymal transition by activating the Smad/Sip1 signaling pathway in CRC. Sci Rep. 2017;7:46078.
   PubMedGoogle Scholar
• Wang G, Nikolic A, Kentish SJ, et al. Loss of BRG1 induces CRC cell senescence by regulating p53/p21 pathway. Cell Death Dis. 2017;8(2):e2607.
   PubMedGoogle Scholar
• Voorneveld PW, Kodach LL, Jacobs RJ, et al. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br J Cancer. 2015;112(1):122–130.
   PubMed Web of Science ®Google Scholar
• Dai Q, Wei HL, Huang J, et al. KRAS polymorphisms are associated with survival of CRC in Chinese population. Tumour Biol. 2016;37(4):4727–4734.
   PubMedGoogle Scholar
• Guo S, Chen D, Huang X, et al. Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. Oncotarget. 2016;7(31):50575–50581.
   PubMedGoogle Scholar
• Poulin EJ, Haigis KM. No back seat for a progression event-K-RAS as a therapeutic target in CRC. Genes Dev. 2017;31(4):333–335.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Salazar R, Tabernero J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am Soc Clin Oncol Educ Book. 2015;35:e149–56.
   Google Scholar
• De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updat. 2015;20:39–70.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Van Bebber SL, Phillips KA, et al. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011;9(1):13–25.
   PubMed Web of Science ®Google Scholar
• Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97(13):981–989.
   PubMedGoogle Scholar
• Jafari A, Matthaei H, Wehner S, et al. Bevacizumab exacerbates sinusoidal obstruction syndrome (SOS) in the animal model and increases MMP 9 production. Oncotarget. 2018;9(31):21797–21810.
   PubMedGoogle Scholar
• Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80.
   PubMed Web of Science ®Google Scholar
• Sunakawa Y, Ichikawa W, Tsuji A, et al. Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials. Clin Colorectal Cancer. 2017;16(3):e171–e180.
   PubMed Web of Science ®Google Scholar
• Barton MK. Primary tumor location found to impact prognosis and response to therapy in patients with metastatic colorectal cancer. CA Cancer J Clin. 2017;67(4):259–260.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Uetake H, Fujita N, et al. TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing Surveillance Study. Clin Colorectal Cancer. 2016;15(4):e205–e211.
   PubMed Web of Science ®Google Scholar
• Price TJ, Hardingham JE, Lee CK, et al. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Med. 2013;2(3):277–285.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Jobin C. The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes. 2013;4(3):253–258.
   PubMed Web of Science ®Google Scholar
• Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu Rev Microbiol. 2016;70:395–411.
   PubMed Web of Science ®Google Scholar
• Candela M, Turroni S, Biagi E, et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 2014;20(4):908–922.
   PubMed Web of Science ®Google Scholar
• Garagnani P, Pirazzini C, Franceschi C. Colorectal cancer microenvironment: among nutrition, gut microbiota, inflammation and epigenetics. Curr Pharm Des. 2013;19(4):765–778.
   PubMed Web of Science ®Google Scholar
• Lucas C, Barnich N, Nguyen HTT. Microbiota, inflammation and colorectal cancer. Int J Mol Sci. 2017;18(6):1310.
   Web of Science ®Google Scholar
• Moossavi S, Zhang H, Sun J, et al. Host-microbiota interaction and intestinal stem cells in chronic inflammation and colorectal cancer. Expert Rev Clin Immunol. 2013;9(5):409–422.
   PubMed Web of Science ®Google Scholar
• Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation, and colorectal cancer. Intest Res. 2018;16(3):338–345.
   PubMed Web of Science ®Google Scholar
• Ray K. Gut microbiota: colorectal cancer-driven by inflammation and gut bacteria? Nat Rev Gastroenterol Hepatol. 2012;9(10):558.
   PubMedGoogle Scholar
• Sun J, Kato I. Gut microbiota, inflammation and colorectal cancer. Genes Dis. 2016;3(2):130–143.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu C, Wu D, et al. gammadelta T cells: crosstalk between microbiota, chronic inflammation, and colorectal cancer. Front Immunol. 2018;9:1483.
   PubMed Web of Science ®Google Scholar
• Nawaz K, Webster RM. The non-small-cell lung cancer drug market. Nat Rev Drug Discov. 2016;15(4):229–230.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2008;6(3):228–269.
   PubMedGoogle Scholar
• Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012;10(10):1236–1271.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer. 2001;34(Suppl 4):S95–101.
   PubMedGoogle Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504–535.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807–821.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Chinelis P, Athanasiadou A, et al. Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases. Respir Med Case Rep. 2017;22:101–105.
   PubMed Web of Science ®Google Scholar
• Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer–recent advances and future perspectives. Int J Cancer. 2016;138(11):2549–2561.
   PubMed Web of Science ®Google Scholar
• Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous nonsmall-cell lung cancer. J Clin Oncol. 2018;36(12):1207–1217.
   PubMed Web of Science ®Google Scholar
• Li XF, Sashittal SG, Chatzizacharias NA, et al. A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer. Medicine (Baltimore). 2015;94(39):e1661.
   PubMed Web of Science ®Google Scholar
• Xu RH, Zhang D, Shen L, et al. A phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer. J Clin Oncol. 2017;35(4):128.
   Web of Science ®Google Scholar